• Explore /
  • Poster
  • / Updated results from a phase 2 study on dalpiciclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01).

Updated results from a phase 2 study on dalpiciclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01).

Abstract Video & Slides Poster

Authors

null

Min Yan

Department of Breast Disease, Henan Breast Cancer Center. The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

Min Yan , Limin Niu , Huimin Lv , Mengwei Zhang , Zhenzhen Liu , Xiuchun Chen , Zhenduo Lu , Chongjian Zhang , Huiai Zeng , Shengnan Zhao , Yajing Feng , Jing Wang , Huihui Sun , Huajun Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT04293276

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 1045)

DOI

10.1200/JCO.2023.41.16_suppl.1045

Abstract #

1045

Poster Bd #

266

Abstract Disclosures

Similar Posters

First Author: Jian Zhang

First Author: Nan Niu

First Author: Lei Liu

First Author: Shuiling Jin